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Abstract
Background: Many people with a high risk of hip fracture have coexisting cardiovascular diseases. We aimed to
examine associations between exposure to antihypertensive drugs and the risk of hip fracture among older people.
Methods: We conducted a cohort study of the 906,422 people born before 1945 and living in Norway in 2005.
We obtained information on all prescriptions of antihypertensive drugs dispensed (the Norwegian Prescription
Database) in 2004–2010 and the dates of primary hip fractures (the Norwegian Hip Fracture Registry) in 2005–2010.
We compared the incidence rates of hip fracture during the time people were exposed and unexposed to
antihypertensive drugs by calculating the standardized incidence ratio (SIR).
Results: Altogether, 39,938 people experienced a primary hip fracture (4.4 %). The risk of hip fracture was decreased
among people exposed to thiazides (SIR 0.7, 95 % confidence interval (CI) 0.6–0.7), beta-blockers (SIR 0.7, 95 % CI 0.7–0.8),
calcium channel blockers (SIR 0.8, 95 % CI 0.8–0.8), angiotensin II receptor blockers (SIR 0.8, 95 % CI 0.7–0.8), ACE
inhibitor/thiazide combination products (SIR 0.7, 95 % CI 0.6–0.7) and angiotensin II receptor blocker/thiazide combination
products (SIR 0.6, 95 % CI 0.6–0.6). Use of loop diuretics and ACE inhibitors (plain products) was associated with increased
fracture risk in people born after 1924, and with decreased risk in those born before 1925. The protective associations
were stronger among exposed men than among exposed women for all drugs except loop diuretics. The SIRs
decreased with increasing age among exposed people, except for thiazides and angiotensin II receptor blockers.
Conclusions: We found a reduced risk of hip fracture associated with overall use of most antihypertensive drugs,
but an increased risk with loop diuretics and ACE inhibitors among people younger than 80 years and in new users of
loop diuretics. This may have great impact at the population level, because the use of antihypertensive drugs is
widespread in people at risk of hip fracture. Clinical studies are needed to further explore these associations.
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Background
Hip fractures represent critical events that seriously affect
morbidity and mortality [1]. The risk of hip fracture in-
creases with age; with estimated lifetime risk of 30 % for
women and 18 % for men in Norway at the age of 50 years
[2]. Many older people with osteoporosis have coexisting
cardiovascular disease such as hypertension, ischemic heart
disease, heart failure and stroke. Both high blood pres-
sure and systolic hypotension have been associated with
falls, reduced bone mineral density (BMD) and hip frac-
ture [3–6].
Antihypertensive drugs are prescribed to more than
half the people aged 60 years and older in Europe and
the United States, in accordance with recommendations
of broad risk assessments, lower limits for blood pres-
sure and ambitious therapeutic goals [7–9]. While obser-
vational studies indicate an increased risk of falls and
hip fracture in older people after initiating antihyperten-
sive drugs [10–12], meta-analyses have revealed no
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associations between long-term treatment and falls [13,
14]. A review of pharmacology, mechanisms and pos-
sible effects on BMD revealed beneficial effects of thia-
zides (reduced renal calcium depletion, direct
stimulation of osteoblasts), beta-blockers (inhibition of
beta-adrenergic receptor in bone), and angiotensin-con-
verting enzyme (ACE) inhibitors (inhibition of ACE in
local renin-angiotensin-aldosterone system); no effect in
either direction of angiotensin II receptor blockers (direct
blockade of angiotensin II receptor) and calcium channel
blockers (inhibition of voltage-gated calcium channel);
negative effects of loop diuretics (increased renal calcium
depletion, risk of falls) [15].
Previous studies of associations between antihyperten-
sive drug use and hip fracture have focused mainly on
diuretics and beta-blockers. While research involving
renin-angiotensin-aldosterone active agents and calcium
channel blockers is limited and diverging, combination
products have not yet been considered. Because these
drugs are widely used, it is important to compare their
impact with other antihypertensive drug groups to in-
form prescribing decisions for older people at risk of
osteoporosis and hip fracture. Based on the Norwegian
Prescription Database and the Norwegian Hip Fracture
Registry, we conducted a nationwide cohort study to
examine associations between exposure to antihyperten-
sive drugs (plain and combination products) and the risk
of hip fracture among people 60 years and older.
Methods
We conducted a cohort study based on data extracted
from three national registries: the Norwegian Prescrip-
tion Database (NorPD) [7], the Norwegian Hip Fracture
Registry [16] and the Central Population Registry [17].
Registries with clinical data on comorbidity were not
available. The model has previously been described in
detail [18].
Registries
The NorPD is a central health registry that contains infor-
mation on all dispensed prescriptions at pharmacies to in-
dividual patients treated in ambulatory care in Norway
since January 2004 [19]. For the purpose of this study, we
extracted data on all prescriptions of antihypertensive
drugs (defined below), dispensed from 1 January 2004 until
31 December 2010, by the items’ Anatomical Therapeutic
Chemical (ATC) system code and drug volume by defined
daily dose (DDD) to individual patients [20]. Prescriptions
dispensed during 2004 were used to identify current drug
users when the study period started on 1 January 2005.
The NorPD does not capture individual information on
drugs dispensed to people staying in hospitals or nursing
homes (about 12,000 and 40,000 at any time). Further, the
NorPD does not comprise clinical data. Reimbursement
codes linked to diagnoses became available from 2009; be-
cause they were not validated against clinical data, we
chose not to include this information.
Since January 2005, all hospitals in Norway performing
operations for hip fracture have reported information on
such surgery to the Norwegian Hip Fracture Registry
[16]. The data extracted for this study comprised the
date of first hip fracture during the study period (here-
after referred to as primary hip fracture), or the date of
surgery in case of missing information, for the period
from 1 January 2005 until 31 December 2010. Although
the registry also contains fractures among patients in
nursing homes and hospitals, these individuals cannot
be identified in the study cohort.
The Central Population Registry contains demographic
information on the entire population of Norway since
1960 [17]. We extracted data on the year of birth, sex
and the date of death or emigration if applicable.
The variables selected from these three registries were
merged, using the unique 11-digit personal identity
number assigned to all residents of Norway after 1960.
Data linkage was performed by a trusted third party
(Statistics Norway).
Study cohort
The study population comprised all people born before
1945 and living in Norway on 1 January 2005. Study
subjects were categorized according to birth year; <1915,
1915–1924, 1925–1934, or 1935–1945. Follow-up con-
tinued until the first of any censoring events, including
the day of any first hip fracture, emigration or death, or
until the end of the study period. The study period
lasted from 1 January 2005 to 31 December 2010.
Antihypertensive drugs
The following medications were considered:
– C03A, Thiazides: hydrochlorthiazide,
bendroflumethiazide/potassium
– C03C, Loop diuretics: furosemide, bumetanide
– C07, Beta-blockers: propanolol, sotalol, metoprolol,
atenolol, bisoprolol, esmolol, labetolol, carvedilol
– C08, Calcium channel blockers: amlodipine,
felodipine, isradipine, nifedipine, nimodipine,
lercanidipine, verapamil, diltiazem
– C09A, ACE inhibitors: captopril, enalapril, lisinopril,
ramipril, trandolapril
– C09B, ACE inhibitor/thiazide: enalapril/thiazide,
lisinopril/thiazide, zofenopril/thiazide
– C09C, Angiotensin II receptor blockers: losartan,
eprosartan, valsartan, irbesartan, candesartan,
telmisartan, olmesartan medoxomil
– C09D, Angiotensin II receptor blockers/thiazide:
losartan/thiazide, eprosartan/thiazide, valsartan/
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thiazide, irbesartan/thiazide, candesartan/thiazide,
telmisartan/thiazide, olmesartan medoxomil/thiazide
C02, Antihypertensives (moxonidine, doxazosin, hydral-
azine, bosentan, ambrisentan) were not included because
they were rarely used in “common” patients.
Drug exposure
The NorPD does not include information on whether or
when the dispensed drugs were consumed; hence, we had
to make assumptions on drug exposure. The DDD is the
assumed average maintenance dose per day for a drug
used for its main indication among adults [20]. Since anti-
hypertensive drugs are prescribed primarily for long-term
use on a daily basis, the number of days corresponding to
the number of DDDs dispensed was used as proxy for the
number of person-days exposed. We assumed that people
started using the drugs on the day they were dispensed.
We defined overall use as all person-days exposed within
the study period (on-treatment definition of exposure). No
gap period was included. We defined recently started use
as the first 14 days of drug exposure after a 365-day wash-
out period.
Statistical analysis
We compared the incidence of primary hip fracture dur-
ing the person-days exposed and unexposed to antihy-
pertensive drugs in the study period by calculating the
standardized incidence ratio (SIR) [21]. An SIR >1 indi-
cates an increased risk of hip fracture associated with
exposure, while an SIR < 1 indicates a decreased risk.
We adjusted the SIR for sex, birth year and time period
(divided into 2-month intervals).
For SIR values based on fewer than 100 observed pri-
mary hip fractures among exposed people, we calculated
exact 95 % confidence intervals (CI) assuming a Poisson
distribution of the observed number of hip fractures (O)
among exposed people, estimating the mean by the ex-
pected number of hip fractures among the exposed
people. When the observed numbers of hip fractures
among exposed people exceeded 100, the 95 % CI values
were approximated by the following formula: [SIR · exp
(−1.96√O), SIR∙ exp (1.96√O)].
To calculate the attributable effect of exposure to anti-
hypertensive drugs on hip fractures, we divided the ob-
served minus the expected number of fractures during the
number of person-days exposed to these drugs by the ob-
served number of fractures in the study population. We
performed analysis using IBM SPSS 19 (PASW Statistics
for Windows, SPSS Inc, Chicago, IL, USA).
Ethics and approvals
The Regional Committee for Medical and Health Re-
search Ethics, REC West (138/07) and the Norwegian
Data Inspectorate (08/00133) approved the study. We ob-
tained permission from the Norwegian Institute of Public
Health regarding data from the Norwegian Prescription
Database (08/2173); from the Norwegian Arthroplasty
Register regarding data from the Norwegian Hip Fracture
Registry (9 June 2009); and from Tax Norway regarding
data from the Central Population Registry (2008/612430).
The Norwegian Directorate of Health granted an exemp-
tion from the duty of confidentiality regarding linkage of
data from the three databases (08/1843). Linkage was per-
formed by a trusted third party (Statistics Norway).
Results
The study cohort comprised 906,422 people (56 % women)
with a mean age of 72.8 years (standard deviation (SD)
8.9 years) on 1 January 2005. The distribution by birth year
and sex is shown in an additional file [see Additional file 1].
The mean follow-up was 5.2 (SD 1.6) years. During the
study period, 218,775 people died (53 % women) and 4949
emigrated (44 % women).
The drugs most frequently used were angiotensin II re-
ceptor blockers (30.5 % of the study cohort; plain products:
16.5 %, combination products: 14.0 %), beta-blockers
(29.8 %) and calcium channel blockers (21.6 %). More
women used diuretics and angiotensin II receptor blockers/
thiazide, and fewer women used beta-blockers and ACE in-
hibitors, as compared with men. Sex differences for other
drug groups were minor. The use of antihypertensive drugs
decreased with age (Table 1).
Altogether, 39,938 (4.4 %) people experienced a pri-
mary hip fracture during the study period. On average,
72 % were women; the proportion increased with age,
from 63 % (born 1934–1944) to 81 % (born <1915).
The mean age at the time of fracture was 83.0 years.
People born in 1925–1934 or 1915–1924 experienced
most fractures (Table 2).
Table 3 shows that exposure to thiazides (SIR 0.7,
95 % CI 0.6–0.7), beta-blockers (SIR 0.7, 95 % CI
0.7–0.8), calcium channel blockers (SIR 0.8, 95 % CI
0.8–0.8), angiotensin II receptor blockers (SIR 0.8,
95 % CI 0.7–0.8), combination products containing
ACE inhibitor/thiazide (SIR 0.7, 95 % CI 0.6–0.7) and
angiotensin II receptor blocker/thiazide (SIR 0.6, 95 %
CI 0.6–0.6) was associated with decreased risk of hip
fracture. Use of loop diuretics and ACE inhibitors
was associated with increased risk of fracture if born
after 1924, and with decreased risk if born before
1925. The SIRs were lower among exposed men than
among exposed women for all drugs except loop di-
uretics. Generally, the SIRs decreased with increasing
age among exposed people, except for thiazides and
angiotensin II receptor blockers (Table 3).
Subanalysis for recently started drug treatment revealed
increased risk of hip fracture during the first 14 days of
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treatment with loop diuretics (all: SIR 1.6, 95 % CI 1.3–
1.9; women: SIR 1.6, 95 % CI 1.2–2.0; men: SIR 1.6,
95 % CI 1.1–2.3). The number of hip fractures during
the first 14 days of treatment was small (n = 257) and re-
vealed no statistically significant results for other drug
classes (Table 4).
Attributable effect for overall exposure was esti-
mated at −3.6 % for angiotensin II receptor blockers/
thiazide, −3.5 % for beta-blockers, and −3.4 % for cal-
cium channel blockers (Table 3).
Discussion
In this registry-based cohort study including the entire
population of Norway aged 60 years and older, we found
a reduction in risk of hip fracture associated with use of
most antihypertensive drugs. However, fracture risk
among users of loop diuretics and plain ACE inhibitors
was increased in people younger than 80 years, and in
new users of loop diuretics.
Methodological considerations
The nationwide cohort design is suitable to compare
people exposed and non-exposed to antihypertensive drugs
with regard to the relatively infrequent outcome, hip frac-
ture, without being prone to selection and recall bias. The
health registries provided us a unique opportunity to link
complete data on all antihypertensive drugs purchased by a
large unselected community-dwelling older population
with all primary hip fractures registered in Norway, and
the 6-year follow-up period yielded a high number of cases.
However, the databases have some limitations. The
NorPD lacks individual information on medications
dispensed to people staying in nursing homes (predom-
inantly long-term care) and hospitals (mostly short
stays), leading to systematic misclassification as drug
non-users. Because frail old people in nursing homes
are particularly prone to both treatment with antihyper-
tensive drugs and hip fracture [22, 23], bias from immeas-
urable exposure time probably caused underestimation of
associations among exposed people. The Norwegian Hip
Fracture Registry comprised about 90 % of all hip fracture
operations in Norway [24], with somewhat lower com-
pleteness during the first years. Unfortunately, clinical in-
formation regarding diagnoses, BMD, functional level,
socioeconomic factors and life style was not available from
the included or any other registry. This hampered adjust-
ments for potentially confounding factors such as fall-risk-
related comorbidities (FRICs), i.e. heart failure, ischemic
heart disease, chronic obstructive lung disease, dementia,
depression, Parkinson’s disease and stroke. Many older
people treated with antihypertensive drugs probably use
other drugs concomitantly, e.g. fall-risk-increasing drugs
(FRIDs) such as other cardiovascular drugs, psychotropics,
opioids and systemic steroids. However, with the time-
varying exposure used in the analysis (SIR), matching
exposure periods for other drugs was not possible. We
consider the time-varying exposure a major strength of
our study, as the alternative, fixed exposure, would have
led to extensive and unmeasurable misclassification yield-
ing unreliable results. In Norway, antihypertensive drugs
are mainly prescribed for hypertension (88–99 % of overall
drug volume); however about 40 % of ACE inhibitors
(plain products) and beta-blockers are prescribed for con-
ditions such as heart failure and ischemic heart disease
[8], and loop diuretics are mainly used for fluid retention.
Because many drugs have several different indications, we
Table 2 Number (n) and incidence rate (%) of hip fracture among
people in Norway during 2005–2010
Hip fractures Birth year
1935–1944 1925–1934 1915–1924 <1915
n % n % n % n %
All (n = 39,938) 4904 1.2 13,322 4.5 18,599 10.1 3153 10.6
Women (n = 28,883) 3086 1.5 9269 5.6 13,982 11.8 2546 11.4
Men (n = 11,055) 1818 0.9 4053 3.1 4577 7.0 607 8.3
Table 1 Percentage of people in Norway born before 1945 who purchased antihypertensive drugs during 2005–2010
Total cohort By sex By birth cohort
n = 906,422 Women Men 1935-1944 1925–1934 1915–1924 <1915
n = 506,568 n = 399, 854 n = 397,761 n = 294,952 n = 183,967 n = 29,742
Thiazide 6.2 7.1 5.2 2.8 2.3 1.0 0.1
Loop diuretic 17.9 19.4 15.9 5.0 7.1 5.3 0.5
Beta blocker 29.8 28.6 31.3 12.1 11.6 5.8 0.3
Calcium channel blocker 21.6 21.5 21.6 8.9 8.4 4.1 0.2
ACE inhibitor 14.0 12.4 16.0 5.4 5.4 2.9 0.3
ACE inhibitor/Thiazide 3.8 2.1 1.7 1.7 1.4 0.7 <0.1
Angiotensin II receptor blocker 16.5 16.8 16.1 7.9 6.0 2.4 0.1
Angiotensin II receptor blocker/Thiazide 14.0 8.1 5.9 7.0 5.1 1.8 0.1
Individuals may have purchased more than one antihypertensive drug type
Ruths et al. BMC Geriatrics  (2015) 15:153 Page 4 of 10
Table 3 Comparison of number of hip fractures (n) during exposed and unexposed person-timea (SIR, 95 % CI)
Total cohort By sex By birth cohort Attributable
effect (%)
Exposed person-days (DDD) Women Men 1935–1944 1925–1934 1915–1924 <1915
n SIR (CI) n SIR (CI) n SIR (CI) n SIR (C)I) n SIR (CI) n SIR (CI) n SIR (CI)
Thiazide 550 0.7 (0.6–0.7) 441 0.7 (0.6–0.8) 109 0.6 (0.5–0.8) 61 0.7 (0.5–0.8) 208 0.6 (0.6–0.7) 258 0.7 (0.6–0.8) 23 0.8 (0.5–1.2) –0.6
Loop diuretic 4752 1.0 (1.0–1.0) 3422 1.0 (0.9–1.0) 1330 1.1 (1.1–1.2) 371 2.0 (1.8–2.3) 1538 1.3 (1.2–1.3) 2543 0.9 (0.8–0.9) 300 0.7 (0.6–0.8) 0.1
Beta blocker 4074 0.7 (0.7–0.8) 3010 0.8 (0.8–0.8) 1064 0.7 (0.6–0.7) 511 0.9 (0.9–1.0) 1700 0.8 (0.8–0.8) 1757 0.7 (0.6–0.7) 106 0.6 (0.5–0.8) –3.5
Calcium channel blocker 5028 0.8 (0.8–0.8) 3736 0.8 (0.8–0.8) 1292 0.7 (0.7–0.8) 642 1.0 (0.9–1.1) 1982 0.8 (0.8–0.8) 2234 0.7 (0.7–0.8) 170 0.7 (0.6–0.8) –3.4
ACE inhibitor 3438 0.9 (0.9–1.0) 2351 1.0 (0.9–1.0) 1087 0.9 (0.8–0.9) 410 1.3 (1.1–1.4) 1389 1.1 (1.0–1.1) 1512 0.8 (0.8–0.8) 127 0.7 (0.6–0.9) –0.6
ACE inhibitor/Thiazide 662 0.7 (0.6–0.7) 520 0.7 (0.6–0.8) 142 0.5 (0.4–0.6) 111 1.9 (0.8–1.2) 264 0.7 (0.6–0.7) 261 0.6 (0.5–0.6) 26 0.9 (0.6–1.3) –0.9
Angiotensin II receptor blocker 2631 0.8 (0.7–0.8) 2041 0.8 (0.8–0.8) 590 0.7 (0.6–0.7) 411 0.9 (0.8–1.0) 1049 0.7 (0.7–0.8) 1094 0.8 (0.7–0.8) 77 0.8 (0.6–1.0) –1.9
Angiotensin II receptor blocker/Thiazide 2122 0.6 (0.6–0.6) 1688 0.6 (0.6–0.7) 434 0.5 (0.4–0.5) 367 0.7 (0.6–0.7) 915 0.6 (0.6–0.6) 790 0.6 (0.5–0.6) 50 0.6 (0.5–0.9) –3.6
SIR Standardized Incidence Ratio, DDD Defined Daily Dose, Attributable effect percentage of hip fractures during DDD exposure throughout the study period
aThe population of Norway born before 1945 and exposed to various antihypertensive drugs in 2005–2010 (exposed person-days, DDD)
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decided not to use drugs as proxies of comorbidities. The
Norwegian Prescription Database includes reimbursement
codes for drugs prescribed for chronic conditions, linked
to ICD-10 diagnoses. We did not consider this informa-
tion because reimbursement codes were neither validated
nor complete (selected drugs only) and not available be-
fore 2009. Previous studies generally revealed protective
associations between hip fracture and antihypertensive
drugs to remain when adjusting for comorbidity, socio-
economic factors, life style and concomitant drug use
[25, 26]; loop diuretics, however, were sensitive for ad-
justment [26].
Because antihypertensive drugs are predominantly used
on a daily basis, we considered the number of days corre-
sponding to the number of DDDs dispensed the best
proxy for the number of drug-exposed person-days. A
study in Germany observed the actually prescribed mean
daily dose (PDD) to be nearly 2.0 DDD for ACE inhibitors
and angiotensin II receptor blockers and close to 1.0 DDD
for beta-blockers, calcium-channel blockers and thiazides
[27]. Consequently, we may have overestimated the ex-
posed person-time, and thus the strength of the associa-
tions between ACE inhibitors and angiotensin II receptor
blockers, and the risk of hip fractures.
Health care in Norway is public and tax-financed; very
low out-of-pocket money and good reimbursement sys-
tems may explain the greater use of newer and more ex-
pensive antihypertensive drugs in Norway compared to
other countries in Europe and North America [9]. One
could suspect that the indication and frequency of treat-
ment with antihypertensive drugs differs in a public health
care setting and a setting with insurance based health care.
Antihypertensive drugs and hip fracture
Different mechanisms have been postulated for effects of
antihypertensive drugs on fracture risk depending on the
duration of drug use; through hypotension and falls in
recently started treatment and through changes in bone
metabolism and bone strength in long-term treatment
[26]. In addition to direct (falls) and indirect (BMD)
drug effects, treatment of the underlying cardiovascular
disease may possible reverse its negative effects on bone
quality and contribute to reduction in fracture risk.
Renin-angiotensin-aldosterone active agents
We found the risk of hip fracture to be decreased with
angiotensin II receptor blockers (plain and combination
products); use of ACE inhibitors was associated with in-
creased risk among users aged <80 years and decreased
among those 80 years and older. The human studies con-
ducted previously have provided conflicting evidence re-
garding the effects of ACE inhibitors on bone metabolism
and fracture risk, whereas angiotensin II receptor blockers
appear to be osteoprotective. A population-based case–
control study in Denmark reported a 14 % reduction in
hip fracture risk (adjusted OR 0.86, 95 % CI 0.80-0.92) in
users of ACE inhibitor compared with nonusers; the crude
OR was not significant. There were no major differences
according to sex, age and drug dosage [25]. Another case–
control study in the United Kingdom revealed a decreased
risk of any fracture for longer-term current users (≥20
prescriptions) of ACE inhibitors (adjusted OR, 0.81; 95 %
CI 0.73–0.89), though, subanalysis for hip fracture was not
conducted. No difference in fracture risk was found with
use of angiotensin II receptor blockers [28]. In a large co-
hort study among low-income older people the United
States, new use of angiotensin II receptor blockers was as-
sociated with a reduction in hip fracture risk (adjusted
Hazard Ratio, HR 0.77, 95 % CI 0.64–0.93) compared with
calcium channel blockers (reference exposure), whereas
no trend was observed for ACE inhibitors (HR 0.95, 95 %
CI 0.84–1.07). Of note, nonusers were not considered, and
Table 4 Recently started antihypertensive drugs; comparison of number of hip fractures during exposed and unexposed person-
timea
Total cohort By sex
Exposed person-days (14 days) Women Men
n SIR (CI) n SIR (CI) n SIR (CI)
Thiazide 16 0.9 (0.5–1.5) 12 0.9 (0.5–1.6) 4 0.8 (0.2–2.2)
Loop diuretic 104 1.5 (1.3–1.9) 76 1.6 (1.2–2.0) 28 1.5 (1.0–2.1)
Beta blocker 47 1.0 (0.7–1.3) 32 1.0 (0.7–1.3) 15 1.0 (0.6–1.6)
Calcium channel blocker 38 1.0 (0.7–1.4) 30 1.1 (0.7–1.5) 8 0.8 (0.3–1.5)
ACE inhibitor 29 1.0 (0.7–1.5) 24 1.3 (0.8–1.9) 5 0.5 (0.2–1.2)
ACE inhibitor/Thiazide 2 0.4 (0.1–1.6) 2 0.6 (0.1–2.2) 0 –
Angiotensin II receptor blocker 11 1.0 (0.5–1.8) 11 1.0 (0.5–1.8) 0 –
Angiotensin II receptor blocker/Thiazide 10 0.5 (0.2–0.9) 8 0.5 (0.2–1.1) 2 0.4 (0–1.4)
SIR Standardized Incidence Ratio
aThe population of Norway born before 1945 and exposed to various antihypertensive drugs in 2005–2010 after 365 days wash out (exposed
person-days, 14 days)
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wash out period (30 days) and follow-up period (median
70 days) were short [26]. In a population-based cohort
study in Sweden, use of renin-angiotensin-aldosterone ac-
tive agents was not associated with altered risk of hip frac-
ture (adjusted OR 0.93, 95 % CI 0.79–1.09); however,
separate analyses for ACE inhibitors and angiotensin II
receptor blockers were not conducted [29]. Another
population-based cohort study in Canada failed to demon-
strate significant differences in hip fracture risk in hyper-
tensive older people treated with angiotensin II receptor
blockers compared to ACE inhibitors (adjusted HR 0.99,
95 % CI 0.78–1.25); nonusers were not considered [30].
The Hypertension in the Very Elderly Trial (HYVET), a
randomized trial with hip fracture as a secondary outcome
measure, revealed that treatment with a thiazide-like diur-
etic ± ACE inhibitor may reduce the risk of hip fracture
[31]. To the best of our knowledge, previous research has
not included combination products. We found protective
associations of ACE inhibitor/thiazide and angiotensin II
receptor blocker/thiazide with hip fracture to be stronger
than for the individual drugs involved. This may possibly
be due to several interacting, beneficial effects on under-
lying cardiovascular disease and bone strength.
A cross-sectional study of hypertensive Chinese men
and women reported associations between ACE inhibitor
use and higher BMD at the hip, after adjusting for diagno-
ses, medications and lifestyle [32]. This finding was not
confirmed by a more recent prospective cohort study in
the United States; ACE inhibitors were associated with hip
bone loss whereas angiotensin II receptor blockers were
not [33]. An open randomized trial showed beneficial ef-
fects of ACE inhibitors ± thiazide in hypertensive people,
i.e. BMD loss was avoided and metabolic profile was im-
proved. Subgroup analysis for ACE polymorphism re-
vealed that beneficial BMD response was confined to
women with the DD polymorphism [34]. Another open
randomized study demonstrated that angiotensin II recep-
tor blockers inhibited bone loss and increased BMD at the
hip in older bed-ridden women, as compared to calcium
channel blockers [35]. In vitro, angiotensin I stimulates
bone resorption in co-cultures of osteoblast and osteo-
clasts, and this action is inhibited by ACE inhibitors [36].
Angiotensin II accelerates bone resorption by activating os-
teoclasts, whereas these effects are blocked by angiotensin
II receptor blockers [37]. Hence, animal studies suggest that
renin-angiotensin-aldosterone active agents inhibit bone re-
sorption, rather than stimulate bone formation [37, 38].
Calcium channel blockers
Our finding of a reduced fracture risk among users of cal-
cium channel blockers is partly in line with the above-
mentioned epidemiologic studies conducted in Denmark
and Sweden. Rejnmark et al. reported a small reduction in
hip fracture risk by 7 % (adjusted OR 0.93, 95 % CI 0.87–
0.99) [25] while Thorell et al. found a reduction by 18 %
(crude OR 0.82, 95 % CI 0.68–0.98); the differences in the
latter study were not maintained, however, after adjust-
ment for age, sex and comorbidity [29]. Although in vitro
studies suggest that calcium-channel blockers may inhibit
osteoclast function [38], previous research has found no
association with hip BMD [32].
Thiazides
Our findings of a reduced hip fracture risk among thiazide-
users align with a Cochrane review including 6 cohort and
15 case–control studies; compared with nonusers, the frac-
ture risk among thiazide users was decreased by 24 %, rela-
tive risk (RR) 0.76 (95 % CI 0.64–0.78) [39]. Randomized
controlled trials have revealed preservation of cortical bone
in older women and men using thiazides, however, fracture
was not an outcome measure [40, 41]. Beneficial effects on
BMD are probably caused by increased renal calcium ab-
sorption, suppressed parathyroid hormone secretion and
enhanced calcium uptake in the intestine, leading to a posi-
tive calcium balance. Further, thiazides directly affect bone
by stimulating osteoblast differentiation [15].
Loop diuretics
The results of our study suggest that risk of hip fracture
with loop diuretics changes with the users’ age; fracture
risk being increased among users aged <80 years, and de-
creased among those 80 years and older. A meta-analysis
of 4 cohort and 9 case–control studies reported a 14 % in-
crease in overall risk of hip fracture among loop diuretic
users compared with nonusers, RR 1.14 (95 % CI 1.08–
1.19) [42]. However, most included studies were adjusted
for age, not allowing for comparison between different age
groups. Some studies have reported sensitivity of risk esti-
mates to adjustment for other confounders (e.g. prior frac-
ture, comorbidity or use of other drugs), revealing smaller
RRs after adjustment [26, 43]. Cohort studies and a ran-
domized controlled trial have reported loss of total hip
BMD among older women and men using loop diuretics
compared with nonusers [44–46]. Interestingly, a recent
study indicated a clinical association of hyponatremia dur-
ing loop diuretic use and an increased risk of osteoporotic
fractures, possible due to exertion of loss of bone sodium
and calcium [47].
Beta-blockers
We found the risk of hip fracture to be decreased with use
of beta-blockers, in accordance with two meta-analyses.
Yang et al. (6 cohort and 7 case–control studies) reported
reduction in risk by 17 % (RR 0.83, 95 % CI 0.70–0.92)
[48], and Toulis et al. (7 cohort and 9 case–control stud-
ies) reduction by 14 % in women (pooled effect size (ES)
0.86, 95 % CI 0.80–0.91) and 20 % in men (ES 0.80, 95 %
CI 0.71–0.90) [49]. Although observational studies have
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associated use of beta-blockers with a higher BMD at the
hip [50–52], randomized trials are lacking. Several studies
suggest the reduction in hip fracture risk to be associated
with β1-selective agents rather than nonselective beta-
blockers [49, 53]. The underlying mechanisms are not yet
clear. Increased sympathetic nervous activity causes an in-
crease in bone resorption and a decrease in bone forma-
tion through stimulation of osteoclasts and inhibition of
osteoblasts. In vitro studies suggest that beta-blockers en-
hance bone formation through blocking input from the
sympathetic nervous system [54].
Recently started drug use
We found increased risk of hip fracture during the first
2 weeks of treatment with loop diuretics; similar findings
have been reported by Berry et al. for the initial 3 weeks of
treatment with thiazides and loop diuretics [12], and by
Butt et al. for the 45 days immediate after a first prescrip-
tion of various antihypertensive drugs (incidence rate ratio
1.43, 95 % CI 1.19–1.72) [11]. Although the numbers of
hip fractures in these studies were relatively small and the
findings must be interpreted with caution, the results are
interesting because they are opposite to those with long-
term drug use. Whereas initiating antihypertensive drugs is
known as risk factor for falls in older people [11], two
meta-analyses revealed no significant associations of falls
with current use of antihypertensive drugs [13, 14]. On the
other hand, a recent population-based study found a dose–
response relationship between drug dose and falls [55].
Age and sex
We found a lower risk of hip fracture among exposed men
than among exposed women. Rejnmark et al. reported
similar trends for sex with regard to beta-blockers, ACE in-
hibitors and calcium channel blockers [25]. Sex hormones
interfere with bone metabolism, posing postmenopausal
women at a much higher risk of hip fracture than men;
most antihypertensive drugs appear to be beneficial for
bone health in both sexes, however, risk differences are
not eliminated.
Generally, we found the protective associations to be
most evident within the youngest cohorts. We probably
underestimated the risk of hip fracture among the oldest
old because the lack of clinical information (confounding
factors could not be adjusted for) and the systematic mis-
classification of the highly exposed [22] nursing home pa-
tients as drug non-users. Amplification of the effects of
these drugs with advancing age may suggest the mainten-
ance of protective drug effects despite other risk factors
such as frailty, osteoporosis, comorbidity and concomitant
drug use. On the other hand, cessation of drug treatment
in the oldest age groups could be associated with general
clinical deterioration (the “healthy user effect”), explaining
the SIRs below 1. The increased hip fracture risk in people
younger than 80 years using loop diuretics and plain ACE
inhibitors, however, may possibly be due to the “more-ill-
user effect” as these drugs are frequently issued to rela-
tively frail people with heart failure.
Conclusions
Our findings support that older people using antihyperten-
sive drugs are at a lower risk of hip fracture compared with
people not using these drugs. Fracture risk among users of
loop diuretics and ACE inhibitors younger than 80 years,
however, was increased. This may have great impact at the
population level, because the use of antihypertensive drugs
is widespread in people at risk of hip fracture. Clinical
studies are needed to further explore these associations.
Even though antihypertensive drugs might be protective
against hip fracture, prescribers should carefully consider
increased vulnerability to hemodynamic side effects when
initiating treatment in older people and practice the key
principle: “start low and go slow.”
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